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Abstract 
Inflammation is a normal part of the immune response to injury or infection but its 
dysregulation promotes the development of inflammatory diseases, which cause considerable 
human suffering. Non-steroidal anti-inflammatory agents (NSAIDs) are the most commonly 
prescribed agents for the treatment of inflammatory diseases but they are accompanied by a 
broad range of side effects, including gastrointestinal and cardiovascular events. The renin-
angiotensin system (RAS) is traditionally known for its role in blood pressure regulation. 
However, there is increasing evidence that RAS signalling is also involved in the inflammatory 
response associated with several disease states. Angiotensin II increases blood pressure by 
binding to angiotensin type 1 (AT1) receptor, and direct renin inhibitors (DRIs), angiotensin-
converting enzyme (ACE) inhibitors and AT1 receptor blockers (ARBs) are clinically used as 
anti-hypertensive agents. Recent data suggest that these drugs also have anti-inflammatory 
effects. Therefore, this review summarizes these recent findings for the efficacy of two of the 
most widely used antihypertensive drug classes, ACE inhibitors and ARBs, to reduce or treat 
inflammatory diseases such as atherosclerosis, arthritis, steatohepatitis, colitis, pancreatitis 
and nephritis. 
Keywords: Renin-angiotensin system; angiotensin-converting enzyme inhibitors; angiotensin 
receptor blockers; inflammatory diseases. 
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1. Introduction 
Inflammation is a normal part of the immune response to injury or infection 
characterized by redness, heat, swelling and pain (Wallach et al., 2014). When this regulation 
fails, inflammation then promotes the development of inflammatory diseases, which cause 
considerable morbidity. Chronic inflammatory conditions cause substantial physical and 
mental disabilities, and the treatment of these diseases remains a therapeutic challenge for 
efficacy and safety reasons (Michetti et al., 2005; Nurmohamed and Dijkmans, 2005). It has 
been reported that non-steroidal anti-inflammatory agents (NSAIDs) are the most commonly 
prescribed agents for the treatment of inflammatory diseases (Papich and Messenger, 2015). 
However, NSAIDs are associated with a broad range of side effects, that include 
gastrointestinal (GI) and cardiovascular events, increased blood pressure, renal toxicity, and 
deterioration of congestive heart failure (Sostres et al., 2013). Thus, novel treatment 
modalities, with fewer side effects, and greater patient satisfaction are required for 
improvement of therapy. 
The renin-angiotensin system (RAS) is best known for its role in blood pressure 
regulation through changes in peripheral vascular resistance and fluid and electrolyte balance 
(Peach, 1977). According to this traditional view, kidney juxtaglomerular cells secrete renin, 
which converts angiotensinogen (the main precursor peptide of RAS) to angiotensin I (Ang I). 
This is then cleaved by angiotensin converting enzyme (ACE) originating from the lung and 
kidney to generate Ang II (the main effector peptide of RAS) (Castrop et al., 2010). Ang II 
exerts its physiological effects by binding to two pharmacologically distinct G-protein coupled 
receptors, Ang II type 1 (AT1) and type 2 (AT2) receptors (Timmermans et al., 1992). Since 
Ang II increases blood pressure via binding to AT1 receptor, direct renin inhibitors (DRIs), 
ACE inhibitors and AT1 receptor blockers (ARBs) are clinically used as anti-hypertensive 
agents (Heran et al., 2008a; Heran et al., 2008b; Webb et al., 2010). 
Interestingly, there is now increasing evidence that RAS signalling also induces 
inflammatory responses in several disease states (Mann, 2002; Marchesi et al., 2008; 
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Montecucco et al., 2009). Ang II stimulation of AT1 receptor, activates nuclear factor (NF)-κB, 
which leads to the production of pro-inflammatory cytokines, chemokines and adhesion 
molecules by resident cells, thereby amplifying the inflammatory responses (Alvarez et al., 
2004; Han et al., 2010; Piqueras et al., 2000). Furthermore, the activation of RAS, particularly 
the two key enzymes renin and ACE, have been implicated in the pathogenesis of several 
inflammatory diseases (Cobankara et al., 2005; Sata and Fukuda, 2010; Shi et al., 2016). 
Preclinical and clinical experiments have revealed that pharmacological blockade of the RAS 
with ACE inhibitors and ARBs is able to diminish the expression of inflammatory mediators 
and is effective in the treatment of pro-inflammatory diseases such as atherosclerosis, 
rheumatoid arthritis, steato-hepatitis, colitis, pancreatitis and nephritis (Chen et al., 2008; 
Flammer et al., 2008; Kuno et al., 2003; Lonn et al., 2001; Nagib et al., 2013; Yokohama et 
al., 2004). The aim of the present review is to summarize the evidence regarding the efficacy 
of RAS pharmacological inhibitors in the treatment of inflammatory diseases. 
 
2. Renin-angiotensin system blockers 
Blockade of the RAS may be accomplished using DRIs, ACE inhibitors or ARBs. ACE 
inhibitors and ARBs are commonly used as antihypertensive agents but are also useful in the 
treatment of other disease states such as chronic kidney disease, chronic heart failure, and 
myocardial infarction, in which the RAS plays a significant role (Remuzzi et al., 2005; Sleight, 
2002; Zucker et al., 2014). These drugs exert their pharmacological effects by preventing the 
downstream activity of Ang II via either decreased production (ACE inhibitors) or receptor 
inhibition (ARBs). In 2007, the first-in-class direct renin inhibitor, aliskiren, was approved as 
an antihypertensive drug with a new strategy in blocking the RAS (Maibaum et al., 2007). DRIs 
decrease the plasma renin activity by binding to its active sites and inhibit the conversion of 
angiotensinogen to Ang I. Currently, data regarding the efficacy of DRIs in reducing blood 
pressure are limited and this class of RAS blockers will not be discussed further in this review. 
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2.1. Angiotensin-converting-enzyme (ACE) inhibitors 
ACE inhibitors can be classified into three main chemical classes according to the zinc 
ion ligand of ACE: i) sulfhydryl-containing ACE inhibitors, structurally related to Captopril (e.g., 
Alacepril, Fentiapril, Pivalpril, and Zofenopril); ii) dicarboxyl-containing ACE inhibitors, 
structurally related to Enalapril (e.g., Benazepril, Cilazapril, Indolapril, Indalapril, Lisinopril, 
Moexipril, Pentopril, Perindopril, Quinapril, Ramipril, and Spirapril); and iii) phosphorus-
containing ACE inhibitors structurally related to Fosinopril (Jackson, 2006; Salvetti, 1990). The 
first ACE inhibitor, Captopril (Capoten), was approved by the Food and Drug Administration 
(FDA) in 1981. Currently, 9 other ACE inhibitors including Benazepril (Lotensin), 
Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and 
Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and 
Trandolapril (Mavik) are also approved for therapeutic use in United States (FDA). 
2.2. Angiotensin receptor blockers (ARB) 
At least seven ARBs are currently available in the US for clinical use. Losartan became 
the first approved ARB in 1995, followed by six others, Valsartan (Diovan), Candesartan 
(Atacand), Irbesartan (Avapro), Telmisartan (Micardis), Olmesartan (Benicar) and Eprosartan 
(Teveten) (Hernández-Hernández et al., 2002). Regarding their chemical structure, five ARBs 
(Valsartan, Candesartan, Irbesartan, Olmesartan, and Losartan) belong to the biphenyl-
tetrazole class. Telmisartan and Candesartan have a common benzimidazole group and the 
other ARB (Eprosartan) has a nonbiphenyl, nontetrazole chemical structure (Taylor et al., 
2011). All ARBs except Irbesartan share a free carboxylic acid group. 
 
3. RAS pharmacological inhibitors in the treatment of inflammatory diseases 
In the following section, we summarize the existing research that explores the 
therapeutic efficacy of RAS pharmacological inhibitors in the treatment of inflammatory 
diseases including atherosclerosis, arthritis, steatohepatitis, colitis, pancreatitis and nephritis. 
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The anti-inflammatory effects of both ACE inhibitors and ARBs that have been reported in 
clinical trials are summarized in Table 1. 
3.1. Atherosclerosis 
Atherosclerosis is an inflammatory response of the arterial wall to the plaque, which is 
associated with high morbidity and mortality (Pagidipati and Gaziano, 2013). Recent evidence 
suggests that RAS plays a crucial role in the pathogenesis of atherosclerosis (Montecucco et 
al., 2009; Sata and Fukuda, 2010). Moreover, it has been found that Ang II has the potential 
to promote atherosclerotic lesions in a murine model of atherosclerosis (ApoE deficient mice) 
(Daugherty et al., 2000). Thus, pharmacological inhibition of RAS appears to interfere with 
development and progression of atherosclerosis. 
3.1.1. ACE inhibitors in the treatment of atherosclerosis 
 The anti-inflammatory and antiatherogenic effects of ACE inhibitors, alone or in 
combination with other drugs, have been investigated in previous preclinical (Chen et al., 
2003; Da Cunha et al., 2005; Hayek et al., 1999; Hayek et al., 2002; Hernández-Presa et al., 
1998; Husain et al., 2010; Knowles et al., 2000; Li et al., 2015a; Ochiai et al., 2002; Schlimmer 
et al., 2011; Shimozawa et al., 2004; Yang et al., 2013) and clinical studies (Ceconi et al., 
2009; Han et al., 2012; Lonn et al., 2001; McMurray et al., 2006; Mitrovic et al., 2005; Zanchetti 
et al., 2004). Shimozawa et al., showed that treatment of human aortic endothelial cells 
(HAECs) with alacepril inhibited the expression of intercellular adhesion molecule 1 (ICAM-1) 
and vascular cell adhesion molecule 1 (VCAM-1) and reduced the adhesion of monocyte 
following treatment with 7-ketocholesterol or tumor necrosis factor (TNF)-α-stimulated HAECs 
(Shimozawa et al., 2004). Quinaprilat treatment was shown to reduce the activation of NF-κB, 
the surface expression of VCAM-1, the production of monocyte chemotactic protein-1 (MCP-
1) and interleukin (IL)-6, and the number of mononuclear leukocytes adhering to endothelial 
cells induced by TNF-α and oxidized low-density lipoprotein (Ox-LDL). These antiatherogenic 
effects of quinaprilat were suggested to be due to increased production of endothelial nitric 
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oxide resulting from activated endothelial nitric oxide synthase (eNOS) (Ochiai et al., 2002). 
In apolipoprotein (Apo) E-deficient mice, enalapril treatment (25 mg/kg/day) prevented the Ang 
II-induced over-expression of adhesion molecules (E-selectin, ICAM-1 and VCAM-1) and 
chemokines MCP-1 in the aorta, while up-regulated the expression of potential anti-
inflammatory transcription factors peroxisome proliferator-activated receptors (PPARs)-α and 
-ƴ, suggesting the role of Ang II-independent mechanisms in the anti-inflammatory and 
antiatherogenic effects of ACE inhibitors (Da Cunha et al., 2005). Treatment of ApoE-deficient 
atherosclerotic mice with enalapril ameliorated the inflammatory and oxidative injury by 
restoring glutathione (GSH) levels and CuZn-SOD and eNOS protein expression and by 
decreasing MCP-1, TNF-α, cyclooxygenase (COX)-2, NADPH oxidase subunit p22phox, 
manganese superoxide dismutase (Mn-SOD) and inducible NOS protein expressions, as well 
as malondialdehyde (MDA) levels. However, the combination of paricalcitol and enalapril was 
more efficacious in aortic inflammatory and oxidative injury (Husain et al., 2010). Furthermore, 
treatment with enalapril interrupted the cycle of atheroma formation and kidney damage in 
mice that were atherosclerotic and hypertensive due to lack of ApoE and eNOS. The observed 
linear relationship between lesion size and blood pressure suggests an important role of 
controlling hypertension in preventing atherosclerotic disease (Knowles et al., 2000). Hayek 
et al. also reported that the anti-atherogenic effects of fosinopril in ApoE-deficient 
atherosclerotic mice were mainly due to blood pressure reduction as well as direct inhibition 
of Ang II actions in the arterial wall such as the inhibition of LDL oxidation (Hayek et al., 1999). 
However, Schlimmer and colleagues reported that the beneficial effects of telmisartan and 
ramipril on endothelial function of aortic and cavernosal tissues in ApoE-deficient mice appear 
to be largely blood pressure-independent and are associated with a reduction of oxidative 
stress as well as expression of eNOS (Schlimmer et al., 2011). The administration of ramipril 
to ApoE-deficient mice with already advanced atherosclerosis was shown to block the 
progression of the atherosclerotic lesion build-up through inhibition of oxidized LDL uptake by 
macrophages (Hayek et al., 2002). In a study investigating the effects of imidapril on 
inflammatory vascular injury, it was demonstrated that not only direct inhibition of Ang II 
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production but also activation of the bradykinin-NO system is involved in the beneficial effects 
of ACE inhibitors on vascular remodeling (Chen et al., 2003). In a rabbit model of 
atherosclerosis, fosinopril treatment significantly decreased the atherosclerotic plaque and 
inhibited the increased expression of Toll-like receptor (TLR)-4 and NF-κB. Yang et al. 
suggested that ACE inhibitor has the potential to be considered as a new anti-atherosclerotic 
drug (Yang et al., 2013). Hernández-Presa and colleagues showed that treatment of 
atherosclerotic rabbits with quinapril results in the attenuation of several parameters 
associated with inflammation including IL-8 and MCP-1 within the atherosclerotic lesions, 
which are controlled by NF-κB (Hernández-Presa et al., 1998). In another study, treatment of 
atherosclerotic rats with captopril (10, 20 mg/kg/day) inhibited the maturation of dendritic cells 
(DCs) and maintained their tolerogenic property, which is associated with DC anti-
atherosclerosis activity. Moreover, captopril treatment promoted IL-10 and transforming 
growth factor (TGF)-β production while decreased that of IL-6 and IL-12 in splenic DCs (Li et 
al., 2015a). Fukuda et al. found that the inhibition of RAS by either ACE inhibitor or ARB 
attenuates peri-adventitial inflammation and reduces atherosclerotic lesion formation. 
However, ACE inhibitors and ARBs may act differently with potential synergistic effects 
(Fukuda et al., 2009). Furthermore, it has been reported that the co-administration of ACE 
inhibitor (quinapril) and statin (atorvastatin) would exert a synergistic effect on vascular 
inflammation, which individual treatment is not able to modify (Oubina et al., 2003). Grothusen 
et al. showed that combination treatment with an ACE inhibitor (ramipril or telmisartan) and 
statin (atorvastatin) might have additive effects on cardiovascular inflammatory markers such 
as IL-6 even in the absence of lipid-reduction (Grothusen et al., 2005). The anti-inflammatory 
effects of ACE inhibitors observed in preclinical studies are reported in Table 2. 
In a clinical trial, 732 patients aged 55 years and over, who had vascular disease or 
diabetes were randomly assigned to receive ramipril 2.5 mg/day or 10 mg/day and vitamin E 
400 IU/day or their matching placebos. Based on the findings reported by Lonn et al., long-
term treatment with ramipril, but not vitamin E, had a beneficial effect on atherosclerosis 
9 
 
progression (Lonn et al., 2001). In an uncontrolled, open-label multicenter study, ACE inhibitor 
therapy with 10 mg ramipril daily significantly reduced serum levels of hs-CRP in patients with 
atherosclerosis, which was suggested to be aside from the blood pressure lowering effect 
(Mitrovic et al., 2005). However, in a study comparing the efficacy of fosinopril (20 mg/day) 
and the diuretic hydrochlorothiazide (25 mg/day) in carotid atherosclerosis progression, 
Zanchetti et al. reported that the greater anti-atherogenic action of fosinopril versus 
hydrochlorothiazide was related to greater BP reduction (Zanchetti et al., 2004). In the 
PERTINENT study, the biomarkers of atherosclerosis and thrombosis were measured at 
baseline and 1 year in a population with stable coronary artery disease, receiving either 
perindopril (8 mg/day) or placebo. The authors observed significant effects of perindopril on 
the pro-inflammatory cytokine, TNF-α, and biomarkers of the atherothrombotic complications 
(D-dimer), but not on biomarkers of inflammation associated with atherosclerosis such as CRP 
and fibrinogen (Ceconi et al., 2009). McMurray et al. compared the effects of captopril, 
valsartan, and their combination on atherosclerotic events in 14,703 patients with acute MI. 
They showed ARBs are as effective as ACE inhibitors in reducing atherosclerotic events and 
their combination may have a small additional anti-infarction effect (McMurray et al., 2006). In 
another study, a total of 40 patients with intermediate CAD were randomly assigned to receive 
either rosuvastatin alone (20 mg/day) or combined rosuvastatin (20 mg/day) and ramipril (10 
mg/day). The authors reported that by adding ramipril to rosuvastatin atheroma volume was 
significantly reduced, which could be partly explained by anti-inflammatory effects (Han et al., 
2012). These findings clearly suggest that the combined therapy with ACE inhibitor and statin 
may be a promising strategy to prevent atherosclerotic disease progression by synergistic 
anti-inflammatory effects. 
3.1.2. ARBs in the treatment of atherosclerosis 
The anti-atherogenic and anti-inflammatory effects of ARBs have been investigated in 
previous pre-clinical (Blessing et al., 2008; Dasu et al., 2009; Fukuda et al., 2010; Ge et al., 
2004; Hadi et al., 2013; Hayashi et al., 2012; Johnstone et al., 2004; Li et al., 2010; Shimada 
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et al., 2011; Strawn et al., 2000; Torres et al., 2014; Xu et al., 2007; Xu et al., 2013; Zhao et 
al., 2014) and clinical studies (Dandona et al., 2003; Gong et al., 2015; Graninger et al., 2004; 
Hirohata et al., 2012; Hirohata et al., 2010; Janic et al., 2014; Koh et al., 2004; Navalkar et al., 
2001; Rahman et al., 2002; Ramadan et al., 2016; Stumpe et al., 2007; Yamamoto et al., 
2011; Yano et al., 2012). Treatment of ApoE-deficient spontaneously hyperlipidemic mice with 
high-dose candesartan caused a clear regression of atherosclerotic lesions by decreasing 
lipid-retaining proteoglycan biglycan and suppressing ACAT1 expression (Hayashi et al., 
2012). In another in vivo study, candesartan exerted anti-inflammatory effects via inhibiting 
the expression of TLR2 and TLR4 (Dasu et al., 2009) which have been shown to promote 
atherosclerosis in animal models (Shinohara et al., 2007). Torres et al., investigated the effects 
of candesartan treatment in hypercholesterolemic rabbits and found reduced expression of 
ICAM-1 and consequent macrophage accumulation in the sclera and choroid (Torres et al., 
2014). Hadi et al. have reported that candesartan reduces cytokine (TNF-α, IL-6, IL-1β) and 
chemokine levels (MCP-1) as well as plasma lipid profile including total cholesterol, 
triglycerides, and LDL-C, whilst also increasing plasma HDL-C levels in treated rabbits. 
Additionally, candesartan significantly attenuated atherosclerosis lesions via interference with 
NF-κB and oxidative pathways (Hadi et al., 2013). Moreover, candesartan attenuated the 
degree of atherosclerosis and reduced both plaque disruption and macrophage accumulation 
while increasing collagen deposition in the aortas of treated rabbits (Johnstone et al., 2004). 
Yao et al. reported that irbesartan attenuated atherosclerosis in high cholesterol-diet ApoE 
knockout mice partly via inhibition of oxidative stress and inflammatory signal transduction 
pathways. Likewise, Zhao et al. suggested remissions of inflammation and apoptosis as 
potential mechanisms mediating the therapeutic effects of irbesartan on atherosclerosis (Zhao 
et al., 2014). Xu et al. reported that the effect of losartan on atherosclerosis is related to 
inhibiting inflammatory process but not lipid metabolism (Xu et al., 2013). In another study, 
losartan exerted an antiatherogenic effect on nonhuman primates possibly through protection 
of LDL from oxidation as well as suppression of vascular monocyte activation and recruitment 
factors (Strawn et al., 2000). Moreover, losartan inhibited atherosclerotic progression in 
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treated rabbits by decreasing macrophage proliferation and accumulation in the arterial wall 
as well as reducing the activation of NF-κB (Xu et al., 2007). Down-regulation of lectin-like 
oxidized LDL receptor-1 (LOX-1) has also been suggested as a potential mechanism for 
attenuating effect of losartan on vein grafts atherosclerosis (Ge et al., 2004). Olmesartan also 
showed anti-atherosclerotic effects by reducing superoxide production and oxidative stress in 
a mouse model of atherosclerosis (Shimada et al., 2011). Moreover, high-cholesterol diet-
induced atherosclerotic lesions in rabbit pulmonary arteries has been shown to be ameliorated 
by treatment with valsartan, possibly through a NO and endothelin-1-dependent mechanism 
(Li et al., 2010). Fukuda et al. suggested that telmisartan has protective effects on the 
development of atherosclerosis beyond AT1 receptor blockade in ApoE-deficient mice (Fukuda 
et al., 2010). Furthermore, Blessing and colleagues showed that chronic treatment with 
telmisartan is more effective than ramipril in reducing the progression of advanced 
atherosclerosis in older ApoE-deficient mice (Blessing et al., 2008). Several studies have also 
found that combination treatment with ARB and statins such as fluvastatin, simvastatin and 
pravastatin produce a greater antiatherogenic effect than monotherapy possibly via the 
combination of the different antiatherosclerotic mechanisms of each drug (Chatzizisis et al., 
2009; Kato et al., 2005; Lee et al., 2012; Li et al., 2004; van der Hoorn et al., 2007; Yang et 
al., 2011). The anti-inflammatory effects of ARBs observed in preclinical studies are reported 
in Table 3. 
In a randomized controlled trial by Graninger et al., twenty-one hypercholesterolemic 
patients received either losartan (50 mg/day) or enalapril (20 mg/day) or placebo for 12 weeks. 
Enalapril and losartan induced a small but stable decrease of circulating ICAM-1 and VCAM-
1, which may indicate an anti-atherogenic effect of angiotensin II blockade in 
hypercholesterolemia (Graninger et al., 2004). In another study, 33 normotensive patients with 
stable CAD were treated with irbesartan for a 24-week period and were compared against a 
control population with no known coronary atherosclerosis. Treatment with irbesartan (75-150 
mg/day) significantly reduced levels of atherosclerotic and inflammatory markers including 
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soluble VCAM-1, soluble TNF-α, and superoxide (Navalkar et al., 2001). In order to investigate 
the effects of ARBs on tissue factor (TF) activity, tissue plasminogen activator (tPA), 
plasminogen activator inhibitor type-1 (PAI-1) antigen levels, plasma renin activity and 
aldosterone levels, losartan (100 mg/day), irbesartan (300 mg/day), and candesartan (16 
mg/day) were administered to 122 hypertensive patients for 2 months. Koh et al. found that 
TF activity, PAI-1 antigen levels, and aldosterone levels were significantly reduced following 
ARB therapy in hypertensive patients (Koh et al., 2004). Three months treatment with 
olmesartan (20 mg/day) promoted the mobilization of endothelial progenitor cells and 
increased the serum levels of eNOS and NO in patients with carotid atherosclerosis (Gong et 
al., 2015). Considering the role of endothelial progenitor cells in repairing damaged blood 
vessels (Werner et al., 2003), the effect of olmesartan on mobilization and function of these 
cells can be considered as a potential antiatherogenic mechanism for ARBs. In a prospective, 
randomized, multicenter trial evaluating the impact of olmesartan on progression of coronary 
atherosclerosis, 247 stable angina pectoris patients with native CAD were randomly assigned 
to receive 10-40 mg of olmesartan or control. Treatment with olmesartan significantly reduced 
total atheroma volume (TAV) and percent change in percent atheroma volume (PAV), which 
suggest a positive role in a potentially lower rate of coronary atheroma progression through 
the administration of olmesartan (Hirohata et al., 2010). In another study on the same 
population, examination of the 4-year clinical outcomes revealed that administration of 
olmesartan in stable angina pectoris patients is associated with reduced incidence of long-
term cardio- and cerebrovascular events, probably due to atheroma volume changes 
(Hirohata et al., 2012). In a double-blind trial, 165 hypertensive patients with carotid wall 
thickening and a defined atherosclerotic plaque were randomized to receive either olmesartan 
(20–40 mg/day) or atenolol (50–100 mg/day). Olmesartan decreased carotid intima-media 
thickness (IMT) and reduced the volume of larger atherosclerotic plaques, independent of its 
blood pressure-lowering effect (Stumpe et al., 2007). Moreover, in subjects with carotid wall 
thickening, 2 years treatment with valsartan (160-320 mg/day) was associated with regression 
in carotid atherosclerosis, which was unaffected by changes in blood pressure (Ramadan et 
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al., 2016). In a study by Rahman and colleagues, 38 subjects with previously undiagnosed 
essential hypertension randomly received 600 mg/day of eprosartan or 50 mg/day of 
hydrochlorothiazide. In this 4-week trial, eprosartan, compared with hydrochlorothiazide, 
effectively reduced systemic blood pressure, neutrophil superoxide anion generating capacity, 
soluble MCP-1, VCAM-1, while increased LDL oxidation lag time, suggesting that eprosartan 
exerts beneficial effects in the vasculature by inhibiting mechanisms of inflammation and 
oxidation (Rahman et al., 2002). Yamamoto et al. compared the effects of losartan and 
amlodipine, a calcium channel blocker, on atherosclerosis of the carotid artery in Japanese 
patients with mild-to-moderate hypertension, left ventricular hypertrophy and diastolic 
dysfunction. Under similar reduction of blood pressure, losartan was more effective than 
amlodipine in protecting the progression of atherosclerosis (Yamamoto et al., 2011). In 
another study on 116 patients with acute myocardial infarction (AMI), additional ARB (5 mg of 
valsartan twice daily) therapy had minimal impact on the progression of coronary 
atherosclerosis as compared with an ACE inhibitor (3 mg of captopril 3 times daily) alone 
(Yano et al., 2012). It has been shown that short-term treatment with valsartan (160 mg/day) 
inhibited reactive oxygen species (ROS) generation, suppressed NF-κB while induced IκB and 
suppressed plasma CRP concentration. However, simvastatin (80 mg/day) and quinapril (40 
mg/day) did not produce similar effects over the period of 1 week (Dandona et al., 2003). 
Furthermore, a low-dose combination of fluvastatin (10 mg/day) and valsartan (20 mg/day) 
decreased inflammatory parameters (hs-CRP and VCAM-1) and increased antioxidant 
defenses (total antioxidant status and glutathione peroxidase) more effective than low-dose 
valsartan alone (Janic et al., 2014). These findings suggest that both inhibition of Ang II 
production and AT1 receptor blockade produce anti-atherogenic and anti-inflammatory effects 
by several mechanisms, particularly inhibiting NF-κB signaling or up-regulating anti-
inflammatory transcription factors PPAR-α and –ƴ. 
3.2. Rheumatoid arthritis 
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Rheumatoid arthritis (RA) is a chronic systemic inflammatory arthritis of autoimmune 
origin characterized by inflammation, persistent synovitis, and eventual joint destruction. RA 
affects up to 1% of the general adult population worldwide (Silman and Pearson, 2002). 
Locally-generated active renin and ACE has been reported to contribute to joint destruction in 
RA (Cobankara et al., 2005). 
3.2.1. ACE inhibitors in the treatment of arthritis 
Several previous studies have evaluated the beneficial anti-arthritic effects of ACE 
inhibitors in animal and human models of arthritis (Agha and Mansour, 2000; Dalbeth et al., 
2004; Flammer et al., 2008; Liu and Wang, 2014; Shi et al., 2012; Tang et al., 2015; Wahba 
et al., 2015). Wahba et al., treated rats with chemically induced RA with ramipril (0.9 
mg/kg/day) that restored all the measured immunological (serum immunoglobulin G and 
antinuclear antibody), inflammatory (serum myeloperoxidase (MPO) and CRP) and oxidative 
stress (MDA and GSH) biomarkers back to normal levels. Specific rheumatoid biomarkers 
including serum rheumatoid factor and cartilage oligomeric matrix protein, but not matrix 
metalloproteinase (MMP)-3, restored back to normal levels, as well (Wahba et al., 2015). 
Similarly, a study investigating the therapeutic effect of captopril treatment in animal model of 
arthritis found that captopril possesses anti-inflammatory and anti-rheumatoid effects through 
reducing TNF-α level in serum of RA rats (Liu and Wang, 2014). Dalbeth et al. showed that 
quinapril (10 mg/kg/day) treatment of mice with collagen-induced arthritis inhibited disease 
activity and reduced articular expression of TNF-α. However, treatment with candesartan (5 
mg/kg/day) also inhibited disease activity in collagen-induced arthritis, suggesting that both 
drugs act predominantly through suppression of Ang II (Dalbeth et al., 2004). In experimentally 
induced-arthritic rats, captopril exerted antiarthritic effects via inhibition of local and systemic 
leukotriene B4 and subsequent reduction of IL-6 levels. In addition, captopril treatment 
reduced elevated levels of lipid peroxide, SOD, and GSH (Agha and Mansour, 2000). The oral 
administration of ramipril (10 mg/kg/day) for 28 days significantly reduced 4-hydroxynonenal 
(HNE) and AT1 receptor levels and restored mitochondrial NADP-isocitrate dehydrogenase 
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(mNADP-ICDH) activity and redox status in left ventricular tissues of adjuvant-induced arthritis 
rats. Ramipril also reduced arthritis scoring and inflammatory markers, suggesting ACE 
inhibition as a novel strategy to prevent heart diseases in RA (Shi et al., 2012). Tang and 
colleagues also reported that captopril is able to attenuate osteoarthritis (OA)-induced 
osteoarticular injury in rats, at least partially, through suppression local RAS (Tang et al., 
2015). Furthermore, in a randomized, double-blind, crossover study, eleven patients with RA 
received ramipril (2.5-10 mg/day) for 8 weeks followed by placebo, or vice versa, in addition 
to standard anti-inflammatory therapy. ACE inhibition with 10 mg/day ramipril markedly 
improved endothelial function in patients with RA (Flammer et al., 2008). These findings clearly 
suggest that ACE inhibitor therapy has a potential therapeutic effect in inflammatory arthritis 
and may provide a novel strategy to prevent cardiovascular events in RA patients. 
3.2.2. ARBs in the treatment of arthritis 
The effects of olmesartan was investigated in zymosan-induced intra-articular 
inflammation in Wistar rats found protective effects for olmesartan in doses of 15 and 30 mg/kg 
as evidenced by improved histopathological parameters of synovium, reduced total leukocyte 
counts, reduced MPO and MDA levels, and increased non-protein sulfhydryl (NPSH) levels. 
Olmesartan also reduced immunostaining for COX-2, TNF-α and IL-17 and increased 
immune-staining for SOD and GPx (Guerra et al., 2016). In a collagen-induced arthritis model, 
ARBs (olmesartan, candesartan, and telmisartan) were administered to mice to investigate 
their preventive or therapeutic effects on the development of arthritis. All ARBs suppressed 
antigen-specific immune responses for Th1 and Th2, and showed therapeutic potential in RA. 
However, olmesartan suppressed the development of severe arthritis and joint destruction, 
even when it was administered only after disease onset (Sagawa et al., 2005). In another 
experimental model of arthritis in rats, losartan (20mg/kg/day) monotherapy not only 
significantly reduced all parameters of inflammation and arthritis but also, when combined with 
methotrexate (1mg/kg/week), provided more effective anti-inflammatory and hepato-
protective effects (Refaat et al., 2013). Price et al. reported that both prophylactic and 
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therapeutic administration of losartan (15 mg/kg) substantially reduced knee joint swelling in 
rats with adjuvant monoarthritis through targeting the angiotensin pathway (Price et al., 2007). 
In two experimental models of arthritis in rats and mice, treatment with losartan decreased 
neutrophil recruitment, hypernociception and the production of TNF-α, IL-1β and chemokine 
ligand 1, which was accompanied by functional improvement of the joint (Silveira et al., 2013). 
Wang and colleagues suggested the up-regulation of AT2 receptor might be a potential 
mechanism by which losartan exerts its therapeutic effects in adjuvant-induced arthritis rats 
(Wang et al., 2013). Losartan also exerted anti-inflammatory and antiosteoclastic effects in 
Aggregatibacter actinomycetemcomitans infection-induced and arthritis-associated alveolar 
bone loss in mice (Queiroz‐Junior et al., 2015). Furthermore, Sakuta et al. suggested that ARB 
therapy reduces vascular damage in adjuvant-induced arthritis in rats by suppressing the 
activity of RAS which is involved in the increased vascular oxidative stress and endothelial 
dysfunction (Sakuta et al., 2010). Similarly, Perry et al. recommended ARBs as the first choice 
antihypertensive agent in patients with RA, since they possess both anti-inflammatory and 
cardiovascular protective effects (Perry et al., 2008). 
3.3. Steatohepatitis 
Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver 
disease (NAFLD) characterized by liver injury and inflammation which often progresses to liver 
fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (Matteoni et al., 1999). Approximately 
3% of individuals in general population may have NASH; although it is more than 25% in 
patients with obesity (Pan and Fallon, 2014). It has been suggested that Ang II plays a role in 
the development and progression of NAFLD throughout the disease spectrum (Morris et al., 
2013). 
3.3.1. ACE inhibitors in the treatment of steatohepatitis 
There are limited numbers of studies evaluating the efficacy of ACE inhibitors in the 
treatment of steatohepatitis and liver fibrosis (Amirshahrokhi et al., 2010; Fayez et al., 2011; 
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Karimian et al., 2008; Reza et al., 2016). In a study conducted on 50 albino Wistar rats, 
treatment of steatohepatitis by oral gavage of either perindopril (3 mg/kg/day) or irbesartan 
(50 mg/kg/day) led to significant amelioration in the biochemical parameters and insulin 
resistance with significant improvement in histopathological grading (Fayez et al., 2011). In a 
hepatic fibrosis rat model, captopril treatment (10 mg/kg/day, orally) increased the hepatic 
content of the anti-inflammatory cytokine IL-10 and decreased the proinflammatory cytokine 
TNF-α, suggesting a cytokine-mediated protective role for captopril on hepatic fibrosis 
(Amirshahrokhi et al., 2010). Likewise, both captopril and enalapril decreased lipid 
peroxidation, increased GSH and improved hepatic fibrosis in the livers of rats with bile duct 
ligation. However, enalapril was shown to be significantly more effective than captopril 
(Karimian et al., 2008). Moreover, ramipril therapy normalized the elevated hepatic enzymes 
activities, improved catalase activity, and reduced hepatic fibrosis in carbon tetrachloride 
(CCl4)-administered rats, which was suggested to be due to inhibition of Ang-II mediated 
oxidative stress and inflammation (Reza et al., 2016). 
3.3.2. ARBs in the treatment of steatohepatitis 
The therapeutic efficacy of ARBs in animal and human models of hepatic steatosis and 
inflammation has been studied in several previous preclinical (Fujita et al., 2007; Kato et al., 
2012; Kudo et al., 2009; Kurita et al., 2008; Kuwashiro et al., 2011; Nakagami et al., 2010; 
Yoshiji et al., 2009) and clinical studies (Alam et al., 2016; Fogari et al., 2012; Hidaka et al., 
2011; Yokohama et al., 2004). Kurita et al., investigated the effects of oral administration of 
olmesartan for 8 weeks suppressed hepatic steatosis and the hepatic expression of lipogenic 
genes in rats with methionine- and choline-deficient diet-induced steatohepatitis. Additionally, 
olmesartan inhibited hepatic oxidative stress and expression of NADPH oxidase as well as 
hepatic fibrosis, stellate cell activation, and expression of fibrogenic genes such as TGF-β and 
PAI-1 (Kurita et al., 2008). In another animal model, treatment with losartan significantly 
attenuated a choline-deficient L-amino acid-defined diet-induced steatohepatitis in rats. In 
addition, the pro-fibrotic cytokine TGF-β was suppressed following administration of losartan 
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(Yoshiji et al., 2009). Eight-week administration of telmisartan (10 mg/kg/day) attenuated 
steatohepatitis progression in mice fed a methionine- and choline-deficient high-fat diet 
through suppressing the macrophage infiltration into the liver and reducing adipocyte size 
(Kudo et al., 2009). Likewise, Kuwashiro et al. found that telmisartan administration increased 
expression of liver PPAR-ƴ, carnitine palmitoyltransferase 1 and acyl-CoA oxidase 1, 
decreased the number of 8-hydroxydeoxyguanosine-positive hepatocytes and reduced the 
infiltration of macrophages into the liver (Kuwashiro et al., 2011). In a study by Nakagami et 
al., telmisartan was effective in improving NASH induced by an L-methionine- and choline-
deficient diet possibly through increased hepatocyte growth factor (HGF) production via partial 
agonist of PPAR-ƴ (Nakagami et al., 2010). Moreover, Fujita and colleagues reported that 
telmisartan, but not valsartan, markedly attenuated hepatic steatosis, inflammation, and 
fibrosis in a rat model of NASH (Fujita et al., 2007). Kato et al. suggested that irbesartan 
administration improved hepatic steatosis by reducing the expression of sterol regulatory 
element-binding protein 1c (SREBP1c) and attenuated the progression of hepatic fibrosis by 
inhibiting the activation of hepatic stellate cells (HSCs) and Kupffer cells as well as reducing 
oxidative stress and pro-inflammatory cytokines (Kato et al., 2012). 
Yokohama conducted a study on seven patients with both NASH and hypertension 
and found that treatment with losartan (50 mg/day for 48 weeks) significantly decreased 
plasma TGF-β1 and serum ferritin concentration concurrently with an improvement in serum 
aminotransferase levels as well as hepatic necroinflammation and fibrosis (Yokohama et al., 
2004). In another study conducted on 150 normocholesterolemic, hypertensive patients with 
nonalcoholic hepatic steatosis, 6-month treatment with losartan (100 mg/day) significantly 
decreased the steatosis degree, subcutaneous adipose tissue (SAT) and visceral adipose 
tissue (VAT) diameter compared with amlodipine therapy. Furthermore, the addition of 
simvastatin improved the therapeutic efficacy of losartan (Fogari et al., 2012). In a 1 year 
randomized control trial, Alam et al. observed that treatment of NASH patients with telmisartan 
together with lifestyle modification improved NAFLD activity score (NAS) and fibrosis score 
19 
 
without any significant adverse events (Alam et al., 2016). In a study conducted by Hidaka et 
al., forty-eight patients with cirrhosis were randomly assigned to receive either olmesartan or 
no therapy for 1 year. Based on the findings, olmesartan significantly reduced TGF-β1, which 
is the key cytokine for liver fibrosis (Hidaka et al., 2011). Taken together, the present findings 
give evidence that ARBs may be therapeutically efficacious for NASH particularly via 
suppressing the expression of pro-fibrotic cytokine TGF-β. 
 
3.4. Colitis 
Inflammatory bowel disease (IBD) is a group of disorders linked to inflammation of GI 
tract and colitis is a type of IBD affecting the inner lining of the colon. Increased colonic 
mucosal Ang I and II concentrations have been observed in Crohn’s colitis, suggesting their 
potential role in the inflammation associated with colitis (Jaszewski et al., 1990). 
3.4.1. ACE inhibitors in the treatment of colitis 
The therapeutic efficacy of pharmaceutical ACE inhibitors has been investigated in 
several animal models of colitis (Jahovic et al., 2005; Koga et al., 2008; Lee et al., 2014; 
Spencer et al., 2007; Sueyoshi et al., 2013; Wengrower et al., 2004). In a study investigating 
the effects of ACE inhibitor therapy on trinitrobenzene sulphonic acid (TNBS)-induced colonic 
inflammation in rats, the injection of captopril (0.1 and 1 mg/kg/day) 5 min after induction of 
colitis suppressed TNF-α production and superoxide generation, but had no effect on colonic 
GSH content. On the other hand, although TNF-α production and lipid peroxidation were 
reduced by injection of lisinopril (0.1 and 1 mg/kg/day), the morphology of the lesions remained 
unchanged, suggesting that captopril is superior to lisinopril in improving colonic inflammation 
(Jahovic et al., 2005). Lee et al. observed that treatment of human intestinal epithelial cell and 
peritoneal macrophages with enalapril significantly inhibited lipopolysaccharide (LPS)-induced 
IκBα phosphorylation, NF-κB binding activity, and pro-inflammatory cytokine production. In 
addition, the administration of enalapril to mice subjected to dextran sulfate sodium (DSS)-
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induced colitis significantly reduced the severity of disease and attenuated the up-regulation 
of IκBα phosphorylation (Lee et al., 2014). Spencer et al., have reported that enalaprilat 
treatment reduced the severity of DSS-induced colitis in mice and reduced epithelial cell 
apoptosis, possibly through suppressing TNF-α mRNA and reducing the ratio of pro-apoptotic 
Bax to anti-apoptotic Bcl-2 (Spencer et al., 2007). Likewise, enalaprilat was shown to be 
effective in reducing disease severity in an IL-10 knockout colitis model, which was minimally 
augmented by prednisolone (Sueyoshi et al., 2013). Furthermore, prophylactic administration 
of captopril reduced the score of macroscopic and histologic lesions and prevented colonic 
fibrosis in TNBS-induced colitis, possibly due to blockade of TGFβ-1 overexpression or direct 
down-regulation of TGFβ-1 transcript (Wengrower et al., 2004). Similarly, Koga et al. found 
that transanal administration of enalaprilat/polyethylene glycol (PEG) is an effective strategy 
to decrease the severity of fibrosis in a DSS-induced colitis model, most likely by down-
regulating the TGF-β signaling pathway (Koga et al., 2008). The findings suggest that ACE 
inhibitor therapy could be a new therapeutic strategy for patients with colitis. 
3.4.2. ARBs in the treatment of colitis 
Similar to ACE inhibitors, ARBs have also been shown to be effective in animal models 
of colitis (Arab et al., 2014; Guerra et al., 2015; Li et al., 2015b; Liu et al., 2016; Nagib et al., 
2013; Okawada et al., 2011). The administration of olmesartan to mice, prior to the induction 
of colitis, dose-dependently ameliorated the UC, which was comparable or even better than 
that of observed in the sulfasalazine-treated group. Additionally, TNF-α, MPO, PGE2, and 
MDA were significantly decreased, while GSH was significantly increased following 
olmesartan therapy. All these beneficial effects were attributed to anti-inflammatory and 
antioxidant properties of olmesartan (Nagib et al., 2013). Likewise, telmisartan treatment (5 
mg/kg) of rats subjected to acetic acid-induced UC significantly reduced levels of TNF-α, MPO, 
and MDA and increased production of IL-10. In addition, macroscopic damage, number of 
ulcers and histopathological processes were reduced following treatment with telmisartan. All 
of these beneficial effects could be explained by decreased TNF-α and increased production 
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of IL-10, together with down-regulation of receptor activator of NF-κB (RANK) and receptor 
activator of NF-κB ligand (RANKL) (Guerra et al., 2015). Li et al. showed that treatment with 
telmisartan not only ameliorated the severity of colitis in IL-10 knockout mice but also 
attenuated mesenteric adipose tissue alteration, at least in part, through suppressing the 
neurotensin/microRNA-155 pathway (Li et al., 2015b). In another study, AT1 receptor blocker 
losartan attenuated TNBS-induced colitis in mice and inhibited the apoptosis of intestinal 
epithelial cell possibly through increasing the Bcl-2/ Bax ratio and down-regulating the 
proapoptotic caspase-3 activity (Liu et al., 2016). Pretreatment of rats subjected to TNBS-
induced colitis with telmisartan attenuated the severity of disease and suppressed the 
inflammatory response via attenuation of TNF-α, PGE2 and MPO activity and restoration of 
IL-10. Telmisartan also inhibited oxidative stress as evidenced by suppression of lipid 
peroxides and NO as well as boosting GSH, total antioxidant capacity (TAC) and the activities 
of SOD and GPx. Additionally, telmisartan suppressed mRNA and protein expression of NF-
kB, p65 and mRNA of COX-2 and inducible NOS proinflammatory genes with concomitant 
upregulation of PPAR-ƴ. Telmisartan also inhibited apoptosis via downregulating the mRNA, 
protein expression and activity of caspase-3, suppressing the elevation of cytochrome c and 
Bax mRNA as well as upregulation of Bcl-2 (Arab et al., 2014). In another study, ARBs 
significantly improved clinical and histologic scores and epithelial cell apoptosis in DSS-
induced colitis in mice. Moreover, TNF-α, IL-1β, and IL6 mRNA were significantly decreased 
with ARB therapy (Okawada et al., 2011). Taken together, these findings support the beneficial 
effects of ARBs in colitis through modulation of inflammation, oxidative stress and apoptosis. 
3.5. Pancreatitis 
Chronic pancreatitis is a relatively common and potentially fatal inflammatory disease, 
which leads to the progressive and irreversible destruction of exocrine and endocrine 
glandular pancreatic parenchyma (Spanier et al., 2008). It has been found that mRNA levels 
of the major RAS components (angiotensinogen, AT1 and AT2 receptors) are expressed in 
pancreatic acinar cells, and they are upregulated during pancreatitis (Tsang et al., 2004). 
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3.5.1. ACE inhibitors in the treatment of pancreatitis 
A limited number of studies have investigated the efficacy of ACE inhibitors in treating 
chronic pancreatitis or alleviating pancreatic inflammation (Chen et al., 2006; Kuno et al., 
2003; Yu et al., 2016). Kuno et al., studied the effects of lisinopril (20, 50, or 200 mg/L in 
drinking water) in rats for 10 weeks significantly alleviated chronic pancreatitis and fibrosis 
through suppressing the expression of TGF-β1 mRNA and subsequent prevention of 
pancreatic stellate cell activation (Kuno et al., 2003). Chen et al. observed that intra-peritoneal 
injection of captopril (4 mg/kg) to rats attenuated vascular permeability by reducing MMP-9 
expression, thereby ameliorating severity of severe acute pancreatitis (Chen et al., 2006). In 
another study, pretreatment of rats with 5 mg/kg captopril 1 hour prior to acute pancreatitis 
induction protected the lung against acute pancreatitis associated lung injury possibly through 
inhibition of Ang II production and the suppression of the Rho/ROCK pathway (Yu et al., 2016). 
3.5.2. ARBs in the treatment of pancreatitis 
Similar to ACE inhibitors, there are few studies investigating the efficacy of ARBs for 
chronic pancreatitis (El-Rahman et al., 2011; Yamada et al., 2003; Yamada et al., 2005). The 
administration of candesartan into drinking water (10.5, 42, or 125 mg/L) of 10-week-old male 
rats for 10 weeks was shown to alleviate chronic pancreatitis and fibrosis by suppressing the 
overexpression of TGF-β1 (Yamada et al., 2003). Moreover, Yamada and colleagues showed 
that combination therapy with candesartan plus lisinopril, but not by either agent alone, 
synergistically alleviated pancreatic inflammation and fibrosis in rats, which was suggested to 
be due to suppression of TNF-α, platelet-derived growth factor-receptor β, and TGF-β1 mRNA 
(Yamada et al., 2005). In another study, losartan was more efficient than pentoxifylline in the 
treatment of L-arginine induced-acute pancreatitis in adult albino rats as indicated by 
histological and biochemical results (El-Rahman et al., 2011). 
3.6. Nephritis 
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Nephritis is an inflammation of one or both kidneys which is categorized into lupus 
nephritis (an autoimmune disease factor leading to the inflammation), glomerulonephritis 
(inflammation of the glomeruli), interstitial nephritis (swelling of the area between the renal 
tubules), and pyelonephritis (swelling due to the spread of a urinary infection to the kidney) 
(Hodgin et al., 2009). 
3.6.1. ACE inhibitors in the treatment of nephritis 
Several in vivo studies have been performed to investigate the beneficial effects of 
ACE inhibitor treatment on nephritis or renal inflammation (Husain et al., 2015; Shinosaki et 
al., 2002; Zhang et al., 2005; Zoja et al., 2003). Shinosaki reported that lisinopril exerted a 
potent antiproteinuric effect on Thy-1.1 induced chronic nephritis in rats, which was attributable 
to protection against glomerular epithelial cells (GEC) damage. The preventive effect of 
lisinopril on extracellular matrix deposition was also attributed to suppression of TGF-β and 
PAI-1 expression (Shinosaki et al., 2002). In another study, fosinopril attenuated renal damage 
in rats with modified immune complex glomerulonephritis through downregulation of signal 
transducer and activator of transcription 3 (STAT-3) activation and ED-1 influx (Zhang et al., 
2005). Moreover, combining lisinopril and L-arginine was reported be effective in reversing 
proteinuria and protecting against renal function impairment in passive Heymann nephritis rats 
(Zoja et al., 2003). Likewise, in a study by Husain et al., combined treatment of ApoE-knockout 
mice with paricalcitol and enalapril significantly ameliorated the renal inflammation and 
oxidative stress (Husain et al., 2015). 
3.6.2. ARBs in the treatment of nephritis 
The efficacy of ARBs in the treatment of nephritis or renal inflammation have been 
examined in several previous preclinical (Chen et al., 2008; Leh et al., 2004; Villa et al., 2011) 
and clinical studies (Qiu et al., 2014; Tsuruoka et al., 2013; Tylicki et al., 2005; Woo et al., 
2008). Chen et al. found that candesartan suppressed redox-sensitive NF-κB-mediated renal 
inflammation by a direct antioxidant effect independent of AT1 receptor blockade in cultured 
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renal tubular epithelial cells (Chen et al., 2008). In another study, both candesartan (4 
mg/kg/day) and pirfenidone (500 mg/kg/day) were found to have beneficial effects on 
proteinuria and morphological changes in rats with chronic anti-glomerular basement 
membrane glomerulonephritis. However, combined treatment resulted in superior 
preservation of morphology (Leh et al., 2004). Villa and colleagues showed that treatment with 
high-dose, but not low-dose, telmisartan ameliorated glomerular and tubulointerstitial damage 
in a rat anti-Thy1.1 model of glomerulonephritis (Villa et al., 2011). 
A 6-year randomized trial in IgA nephritis showed that high dose losartan (200 mg/day) 
was more efficacious in reducing proteinuria as well as preserving renal function when 
compared with normal dose losartan (100 mg/day) and enalapril (20 mg/day) (Woo et al., 
2008). In a randomized controlled trial conducted by Qiu et al., irbesartan significantly reduced 
proteinuria in 479 patients with primary chronic glomerulonephritis. However, its combination 
with Rehmannia glutinosa acteosides yielded a greater reduction in proteinuria (Qiu et al., 
2014). Moreover, in an open, randomized, 12-month study, 10 mg of enalapril and 25 mg of 
losartan equally reduced proteinuria in 34 patients with primary glomerulonephritis (Tylicki et 
al., 2005). In a study investigating the anti-inflammatory effects of irbesartan in 29 nondiabetic 
hypertensive patients with chronic glomerulonephritis, treatment with irbesartan for 26 weeks 
significantly decreased proteinuria and improved the concentrations of adiponectin and 
hsCRP (Tsuruoka et al., 2013). Thus, ARBs may be beneficial for reducing proteinuria and 
inflammatory markers in patients with nephritis or renal inflammation. 
 
4. Conclusion 
In this paper, we have reviewed the anti-inflammatory effects of two of the most widely 
used antihypertensive drug classes. The potential mechanisms responsible for these anti-
inflammatory effects are presented in Figure 1. Given the above, it seems that both ACE 
inhibitors and ARBs are effective pharmacological treatments for a wide variety of 
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inflammatory diseases such as atherosclerosis, arthritis, steatohepatitis, colitis, pancreatitis 
and nephritis. Moreover, their combination with some other drugs such as statins can further 
improve the anti-inflammatory properties of these drugs. However, long-term trials are 
required before a final recommendation can be made for their use a primary or adjunctive 
therapy for patients with inflammatory diseases. 
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Table 1. Anti-inflammatory activities of ACE inhibitors and ARBs in clinical trials 
Author Inflammatory 
condition 
Sample size Drug (Dosage) Findings 
Lonn et al. (2001) Atherosclerosis 732 patients Ramipril (2.5 mg/day or 10 
mg/day) and/or vitamin E (400 
IU/day) 
Long-term treatment with ramipril, but not vitamin E, had 
a beneficial effect on atherosclerosis progression. 
Mitrovic et al. (2005) Atherosclerosis 24 patients Ramipril (10 mg/day) Treatment with ramipril significantly reduced serum 
levels of hs-CRP in patients with atherosclerosis. 
Zanchetti et al. (2004) Atherosclerosis 508 patients Fosinopril (20 mg/day) or 
hydrochlorothiazide (25 
mg/day) 
Progression of carotid atherosclerosis occurred with 
hydrochlorothiazide but not with fosinopril. 
Ceconi et al. (2009) Atherosclerosis 1157 patients Perindopril (8 mg/day) ACE inhibition had significant effects on biomarkers of 
the atherothrombotic complications (D-dimer) and the 
proinflammatory cytokine TNF-α, but not on biomarkers 
of inflammation associated with atherosclerosis (CRP 
and fibrinogen). 
McMurray et al. (2006) Atherosclerosis 14,703 
patients 
Captopril (150 mg/day) and/or 
valsartan (160-320 mg/day) 
Valsartan was as effective as captopril in reducing 
atherosclerotic events and their combination had a small 
additional anti-infarction effect. 
Han et al. (2012) Atherosclerosis 40 patients Rosuvastatin (20 mg/day) 
and/or ramipril (10 mg/day) 
Adding ramipril to rosuvastatin significantly reduced 
atheroma volume, which could be partly explained by 
anti-inflammatory effects. 
Graninger et al. (2004) Atherosclerosis 21 patients Losartan (50 mg/day) or 
enalapril (20 mg/day) 
Enalapril and losartan induced a small but stable 
decrease of circulating ICAM-1 and VCAM-1. 
Navalkar et al. (2001) Atherosclerosis 33 patients Irbesartan (75-150 mg/day) Treatment with irbesartan significantly reduced levels of 
atherosclerotic and inflammatory markers including 
soluble VCAM-1, soluble TNF-α, and superoxide. 
Koh et al. (2004) Atherosclerosis 122 patients Losartan (100 mg/day), 
irbesartan (300 mg/day), and 
candesartan (16 mg/day) 
TF activity, PAI-1 antigen levels, and aldosterone levels 
were significantly reduced following ARB therapy in 
hypertensive patients. 
Gong et al. (2015) Atherosclerosis 40 patients Olmesartan (20 mg/day) Treatment with olmesartan promoted the mobilization of 
endothelial progenitor cells and increased the serum 
levels of eNOS and NO. 
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Hirohata et al. (2010) Atherosclerosis 247 patients Olmesartan (10-40 mg/day) Treatment with olmesartan significantly reduced TAV 
and percent change in PAV. 
Hirohata et al. (2012) Atherosclerosis 247 patients Olmesartan (10-40 mg/day) Administration of olmesartan in stable angina pectoris 
patients was associated with reduced incidence of long-
term cardio- and cerebrovascular events. 
Stumpe et al. (2007) Atherosclerosis 165 patients Olmesartan (20–40 mg/day) 
or atenolol (50–100 mg/day) 
Olmesartan decreased carotid IMT and reduced the 
volume of larger atherosclerotic plaques. 
Ramadan et al. (2016) Atherosclerosis 120 patients Valsartan (160-320 mg/day) Treatment with valsartan was associated with 
regression in carotid atherosclerosis. 
Rahman et al. (2002) Atherosclerosis 38 patients Eprosartan (600 mg/day) or 
hydrochlorothiazide (50 
mg/day)  
Eprosartan, compared with hydrochlorothiazide, 
effectively reduced systemic blood pressure, neutrophil 
superoxide anion generating capacity, soluble MCP-1, 
VCAM-1. 
Yamamoto et al. 
(2011) 
Atherosclerosis 57 patients Losartan (50 mg/day) or 
amlodipine (2.5 mg/day) 
Losartan was more effective than amlodipine in 
protecting the progression of atherosclerosis. 
Yano et al. (2012) Atherosclerosis 116 patients Captopril (9 mg/day) and/or 
valsartan (10 mg/day) 
Additional ARB therapy had minimal impact on the 
progression of coronary atherosclerosis as compared 
with an ACE inhibitor alone. 
Dandona et al. (2003) Atherosclerosis 32 patients Valsartan (160 mg/day) or 
simvastatin (80 mg/day) or 
quinapril (40 mg/day) 
Short-term treatment with valsartan inhibited ROS 
generation, suppressed NF-κB while induced IκB and 
suppressed plasma CRP concentration. 
Janic et al. (2014) Atherosclerosis 130 patients Valsartan (20 mg/day) and/or 
fluvastatin (10 mg/day) 
A low-dose combination of fluvastatin and decreased 
inflammatory parameters (hs-CRP and VCAM-1) and 
increased antioxidant defenses (total antioxidant status 
and glutathione peroxidase) more effective than low-
dose valsartan alone. 
Flammer et al. (2008) Rheumatoid 
arthritis 
11 patients Ramipril (2.5-10 mg/day) ACE inhibition with 10 mg/day ramipril markedly 
improved endothelial function in patients with RA. 
Perry et al. (2008) Rheumatoid 
arthritis 
138 patients Losartan or ramipril Patients taking an ARB had significantly lower ESR 
levels compared with controls. 
Yokohama et al. 
(2004) 
Steatohepatitis 7 patients Losartan (50 mg/day Treatment with losartan significantly decreased plasma 
TGF-β1 and serum ferritin concentration concurrently 
with an improvement in serum aminotransferase levels 
as well as hepatic necroinflammation and fibrosis. 
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Fogari et al. (2012) Steatohepatitis 150 patients Losartan (100 mg/day) Six-month treatment with losartan significantly 
decreased the steatosis degree, SAT and VAT diameter 
compared with amlodipine therapy. 
Alam et al. (2016) Steatohepatitis 50 patients Telmisartan (40-80 mg/day) Telmisartan improved NAS and fibrosis score in NASH 
with insignificant adverse events. 
Hidaka et al. (2011) Steatohepatitis 48 patients Olmesartan (10-40 mg/day) Olmesartan significantly reduced TGF-β1, which is the 
key cytokine for liver fibrosis. 
Woo et al. (2008) Nephritis 226 patients Losartan (100 mg/day or 200 
mg/day) or enalapril (10 
mg/day or 20 mg/day) 
High dose losartan was more efficacious in reducing 
proteinuria as well as preserving renal function when 
compared with normal dose losartan and enalapril. 
Qiu et al. (2014) Nephritis 479 patients Irbesartan (150 mg/day) Irbesartan significantly reduced proteinuria in patients 
with primary chronic glomerulonephritis. 
Tylicki et al. (2005) Nephritis 34 patients Enalapril (10 mg/day) and 
losartan (25 mg/day) 
Enalapril and losartan equally reduced proteinuria in 
patients with primary glomerulonephritis. 
Tsuruoka et al. (2013) Nephritis 29 patients Irbesartan (100-200 mg/day) Treatment with irbesartan significantly decreased 
proteinuria and improved the concentrations of 
adiponectin and hsCRP. 
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Table 2. Anti-inflammatory effects of ACE inhibitors in preclinical studies 
 Expression/ 
production 
Quinapril/ 
Quinaprilat 
Enalapril/ 
Enalaprilat 
Ramipril Captopril Fosinopril Alacepril Lisinopril 
ICAM-1 Decrease  (Da Cunha et al., 
2005) 
   (Shimozawa 
et al., 2004) 
 
VCAM-1 Decrease (Ochiai et al., 
2002) 
(Da Cunha et al., 
2005) 
   (Shimozawa 
et al., 2004) 
 
E-selectin Decrease  (Da Cunha et al., 
2005) 
     
MCP-1 Decrease (Hernández-
Presa et al., 
1998) 
(Da Cunha et al., 
2005) 
(Husain et al., 2010) 
     
IL-8 Decrease (Hernández-
Presa et al., 
1998) 
      
TNF-α Decrease (Dalbeth et al., 
2004) 
(Husain et al., 2010) 
(Spencer et al., 
2007) 
(Shi et al., 
2012) 
(Liu and Wang, 
2014) 
(Amirshahrokhi 
et al., 2010) 
(Jahovic et al., 
2005) 
  (Jahovic et 
al., 2005) 
IL-6 Decrease (Ochiai et al., 
2002) 
 (Grothusen 
et al., 2005) 
(Li et al., 
2015a) 
(Agha and 
Mansour, 
2000) 
   
IL-12 Decrease    (Li et al., 
2015a) 
   
IL-10 Increase    (Li et al., 
2015a) 
(Amirshahrokhi 
et al., 2010) 
   
NF-κB Decrease (Ochiai et al., 
2002) 
(Lee et al., 2014)   (Yang et al., 
2013) 
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STAT-3 Decrease     (Zhang et al., 
2005) 
  
PPAR-α Increase  (Da Cunha et al., 
2005) 
     
PPAR-ƴ Increase  (Da Cunha et al., 
2005) 
     
MMP-9 Decrease    (Chen et al., 
2006) 
   
MPO Decrease   (Wahba et 
al., 2015) 
    
COX-2 Decrease  (Husain et al., 2010)      
iNOS Decrease  (Husain et al., 2010)      
eNOS Increase (Ochiai et al., 
2002) 
(Husain et al., 2010) (Hayek et al., 
1999) 
    
CRP Decrease   (Wahba et 
al., 2015) 
    
PGE2 Decrease   (Shi et al., 
2012) 
    
LTB4 Decrease    (Agha and 
Mansour, 
2000) 
   
TGF-β Decrease  (Koga et al., 2008)  (Wengrower et 
al., 2004) 
  (Kuno et al., 
2003) 
(Shinosaki et 
al., 2002) 
Increase    (Li et al., 
2015a) 
 
   
TLR-4 Decrease     (Yang et al., 
2013) 
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Table 3. Anti-inflammatory effects of ARBs in preclinical studies 
 Expression/ 
production 
Candesartan Losartan Olmesartan Telmisartan Irbesartan Valsartan 
ICAM-1 Decrease (Torres et al., 2014)      
MCP-1 Decrease (Hadi et al., 2013)      
TNF-α Decrease (Hadi et al., 2013) (Refaat et al., 2013) 
(Silveira et al., 2013) 
(Guerra et al., 
2016) 
(Fujita et al., 2007) (Kato et al., 
2012) 
(Fujita et al., 
2007) 
IL-1β Decrease (Hadi et al., 2013) (Refaat et al., 2013) 
(Silveira et al., 2013) 
    
IL-6 Decrease (Hadi et al., 2013)      
IL-17 Decrease   (Guerra et al., 
2016) 
   
NF-κB Decrease (Hadi et al., 2013) 
(Chen et al., 2008) 
(Xu et al., 2007)     
PPAR-ƴ Increase    (Kuwashiro et al., 
2011) 
(Zhao et al., 
2014) 
 
MPO Decrease   (Guerra et al., 
2016) 
   
COX-2 Decrease   (Guerra et al., 
2016) 
   
iNOS Decrease    (Arab et al., 2014)   
CRP Decrease  (Refaat et al., 2013)     
TGF-β Decrease (Yamada et al., 
2003) 
(Yoshiji et al., 2009) (Kurita et al., 
2008) 
(Fujita et al., 2007)   
TLR-2 Decrease (Dasu et al., 2009)      
TLR-4 Decrease (Dasu et al., 2009)      
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